Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia.
CAT-8015
moxetumomab
pediatric
pharmacokinetics
safety
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
19
07
2019
revised:
11
10
2019
accepted:
10
11
2019
pubmed:
17
1
2020
medline:
14
7
2020
entrez:
17
1
2020
Statut:
ppublish
Résumé
In a multicenter phase 1 study of children with relapsed/refractory acute lymphoblastic leukemia (ALL), moxetumomab pasudotox, an anti-CD22 immunotoxin, demonstrated a manageable safety profile and preliminary evidence of clinical activity. A phase 2 study further evaluated efficacy. This international, multicenter, phase 2 study enrolled children with relapsed/refractory B-cell precursor ALL who received moxetumomab pasudotox 40 µg/kg intravenously every other day, for six doses per 21-day cycle. The primary objective was to evaluate the complete response (CR) rate. Secondary objectives included safety, pharmacokinetics, and immunogenicity evaluations. Thirty-two patients (median age, 10 years) were enrolled at 16 sites; 30 received study drug and were evaluable for safety; 28 were evaluable for response. The objective response rate was 28.6%, with three patients (10.7%) achieving morphologic CR, and five patients (17.9%) achieving partial response. Disease progression occurred in 11 patients (39.3%). Ten patients (33.3%) experienced at least one treatment-related serious adverse event, including capillary leak syndrome (CLS; n = 6), hemolytic uremic syndrome (HUS; n = 4), and treatment-related death (n = 1) from pulmonary edema. No differences were observed in inflammatory markers in patients who did or did not develop CLS or HUS. Despite a signal for clinical activity, this phase 2 study was terminated at interim analysis for a CR rate that did not reach the stage 1 target. Preclinical data suggest enhanced efficacy of moxetumomab pasudotox via continuous infusion or in combination regimens; thus, further studies designed to optimize the efficacy and safety of moxetumomab pasudotox in pediatric ALL may be warranted.
Sections du résumé
BACKGROUND
In a multicenter phase 1 study of children with relapsed/refractory acute lymphoblastic leukemia (ALL), moxetumomab pasudotox, an anti-CD22 immunotoxin, demonstrated a manageable safety profile and preliminary evidence of clinical activity. A phase 2 study further evaluated efficacy.
PROCEDURE
This international, multicenter, phase 2 study enrolled children with relapsed/refractory B-cell precursor ALL who received moxetumomab pasudotox 40 µg/kg intravenously every other day, for six doses per 21-day cycle. The primary objective was to evaluate the complete response (CR) rate. Secondary objectives included safety, pharmacokinetics, and immunogenicity evaluations.
RESULTS
Thirty-two patients (median age, 10 years) were enrolled at 16 sites; 30 received study drug and were evaluable for safety; 28 were evaluable for response. The objective response rate was 28.6%, with three patients (10.7%) achieving morphologic CR, and five patients (17.9%) achieving partial response. Disease progression occurred in 11 patients (39.3%). Ten patients (33.3%) experienced at least one treatment-related serious adverse event, including capillary leak syndrome (CLS; n = 6), hemolytic uremic syndrome (HUS; n = 4), and treatment-related death (n = 1) from pulmonary edema. No differences were observed in inflammatory markers in patients who did or did not develop CLS or HUS.
CONCLUSIONS
Despite a signal for clinical activity, this phase 2 study was terminated at interim analysis for a CR rate that did not reach the stage 1 target. Preclinical data suggest enhanced efficacy of moxetumomab pasudotox via continuous infusion or in combination regimens; thus, further studies designed to optimize the efficacy and safety of moxetumomab pasudotox in pediatric ALL may be warranted.
Identifiants
pubmed: 31944549
doi: 10.1002/pbc.28112
pmc: PMC7485266
mid: NIHMS1060840
doi:
Substances chimiques
Bacterial Toxins
0
Biomarkers, Tumor
0
Exotoxins
0
immunotoxin HA22
2NDX4B6N8F
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28112Subventions
Organisme : NCI NIH HHS
ID : P30 CA014089
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001855
Pays : United States
Organisme : NCI NIH HHS
ID : P30CA014089
Pays : United States
Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
J Immunother. 2017 Jun;40(5):187-195
pubmed: 28441264
Clin Cancer Res. 2019 Sep 1;25(17):5329-5341
pubmed: 31110075
Leuk Lymphoma. 2011 Jun;52 Suppl 2:11-3
pubmed: 21504292
J Clin Oncol. 2012 May 20;30(15):1822-8
pubmed: 22355053
Leukemia. 2018 Aug;32(8):1768-1777
pubmed: 30030507
J Clin Oncol. 2014 Dec 20;32(36):4134-40
pubmed: 25385737
Nat Commun. 2016 Jul 27;7:12320
pubmed: 27460500
J Immunol Methods. 2016 Aug;435:68-76
pubmed: 27220271
Leukemia. 2019 Apr;33(4):884-892
pubmed: 30267011
Blood. 2017 Oct 5;130(14):1620-1627
pubmed: 28983018
Proc Natl Acad Sci U S A. 2018 Feb 20;115(8):E1867-E1875
pubmed: 29432154
Clin Cancer Res. 2011 Oct 15;17(20):6398-405
pubmed: 22003067
Blood. 2015 Aug 20;126(8):964-71
pubmed: 26124497
N Engl J Med. 2018 Feb 1;378(5):449-459
pubmed: 29385376
Blood. 2016 May 19;127(20):2406-10
pubmed: 26907630
Cancer Discov. 2015 Dec;5(12):1282-95
pubmed: 26516065
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Lancet. 2015 Feb 7;385(9967):517-528
pubmed: 25319501
Cancer. 2018 Apr 15;124(8):1722-1732
pubmed: 29381191
Pediatr Blood Cancer. 2015 Jun;62(6):964-9
pubmed: 25728039
N Engl J Med. 2016 Aug 25;375(8):740-53
pubmed: 27292104
Blood. 2007 Feb 1;109(3):926-35
pubmed: 17003380
Toxins (Basel). 2018 May 21;10(5):
pubmed: 29883379
Nat Med. 2018 Jan;24(1):20-28
pubmed: 29155426
Leukemia. 2019 Dec;33(12):2854-2866
pubmed: 31110217
J Clin Oncol. 2016 Dec 20;34(36):4381-4389
pubmed: 27998223
Cancer. 2019 Jul 15;125(14):2474-2487
pubmed: 30920645
Blood. 2018 May 24;131(21):2331-2334
pubmed: 29487070